Biotech Values

[DewDiligence]

More on RNAI’s program in HCV:

The name of the drug is Sirna-034, and it consists of two siRNA’s each of which targets a different conserved region of the HCV virus. (Hence the quote in message #32730.)

RNAI expects to file an IND before year-end to test Sirna-034 monotherapy given by IV in treatment-refractory, genotype-1 patients.

The first part of the trial will test single ascending doses; then, depending on the duration of effect, the second part of the trial will test multiple doses using a weekly or less frequent schedule.

Sub-Q and oral formulations are under development for a later trial.

In primate tests, Sirna-034 produced a 3.5-4.0 log reduction in viral load over 4 weeks.